Ngm Biopharmaceuticals Stock Filter Stocks by Fundamentals
NGMDelisted Stock | USD 2.50 0.14 5.30% |
NGM Biopharmaceuticals fundamentals help investors to digest information that contributes to NGM Biopharmaceutica's financial success or failures. It also enables traders to predict the movement of NGM Stock. The fundamental analysis module provides a way to measure NGM Biopharmaceutica's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NGM Biopharmaceutica stock.
NGM |
Did you try this?
Run Instant Ratings Now
Instant RatingsDetermine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |
All Next | Launch Module |
NGM Fundamentals
Return On Equity | -0.7 | |||
Return On Asset | -0.38 | |||
Operating Margin | (179.78) % | |||
Current Valuation | (36.13 M) | |||
Shares Outstanding | 83.46 M | |||
Shares Owned By Insiders | 21.08 % | |||
Shares Owned By Institutions | 54.16 % | |||
Number Of Shares Shorted | 1.68 M | |||
Price To Earning | (21.12) X | |||
Price To Book | 0.86 X | |||
Price To Sales | 29.10 X | |||
Revenue | 4.42 M | |||
Gross Profit | (125.73 M) | |||
EBITDA | (144.33 M) | |||
Net Income | (142.38 M) | |||
Cash And Equivalents | 297.81 M | |||
Cash Per Share | 3.71 X | |||
Total Debt | 5.38 M | |||
Debt To Equity | 0.03 % | |||
Current Ratio | 7.49 X | |||
Book Value Per Share | 1.79 X | |||
Cash Flow From Operations | (132.2 M) | |||
Short Ratio | 1.26 X | |||
Earnings Per Share | (1.73) X | |||
Target Price | 1.66 | |||
Number Of Employees | 138 | |||
Beta | 1.26 | |||
Market Capitalization | 128.53 M | |||
Total Asset | 168.87 M | |||
Retained Earnings | (724.01 M) | |||
Working Capital | 136.36 M | |||
Current Asset | 330.81 M | |||
Current Liabilities | 43.69 M | |||
Net Asset | 168.87 M |
About NGM Biopharmaceutica Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NGM Biopharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NGM Biopharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NGM Biopharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Other Consideration for investing in NGM Stock
If you are still planning to invest in NGM Biopharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NGM Biopharmaceutica's history and understand the potential risks before investing.
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |